Cargando…
Humoral and cellular correlates of a novel immune-related adverse event and its treatment
Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE trea...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655605/ https://www.ncbi.nlm.nih.gov/pubmed/34880115 http://dx.doi.org/10.1136/jitc-2021-003585 |
_version_ | 1784612108597460992 |
---|---|
author | Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L Karp, David Li, Quan-Zhen Wakeland, Edward K Gerber, David E |
author_facet | Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L Karp, David Li, Quan-Zhen Wakeland, Edward K Gerber, David E |
author_sort | Gonugunta, Amrit S |
collection | PubMed |
description | Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE treated with corticosteroids. Through assessment of longitudinal biospecimens, we analyzed serial autoantibodies, cytokines, and cellular populations. Months after ICI initiation and preceding clinical toxicity, the patient developed broad increases in cytokines (most notably interleukin-6 (IL-6), interferon-γ (IFNγ), C-X-C motif chemokine ligand 2 (CXCL2), and C–C motif chemokine ligand 17 (CCL17)), autoantibodies (including anti-angiotensin receptor, α-actin, and amyloid), CD8 T cells, and plasmablasts. Such changes were not observed in healthy controls and ICI-treated patients without irAE. Administration of corticosteroids resulted in immediate and profound decreases in cytokines, autoantibodies, and inflammatory cells. This case highlights the potential for late-onset changes in humoral and cellular immunity in patients receiving ICI. It also demonstrates the biologic effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management. |
format | Online Article Text |
id | pubmed-8655605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86556052021-12-27 Humoral and cellular correlates of a novel immune-related adverse event and its treatment Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L Karp, David Li, Quan-Zhen Wakeland, Edward K Gerber, David E J Immunother Cancer Case Report Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE treated with corticosteroids. Through assessment of longitudinal biospecimens, we analyzed serial autoantibodies, cytokines, and cellular populations. Months after ICI initiation and preceding clinical toxicity, the patient developed broad increases in cytokines (most notably interleukin-6 (IL-6), interferon-γ (IFNγ), C-X-C motif chemokine ligand 2 (CXCL2), and C–C motif chemokine ligand 17 (CCL17)), autoantibodies (including anti-angiotensin receptor, α-actin, and amyloid), CD8 T cells, and plasmablasts. Such changes were not observed in healthy controls and ICI-treated patients without irAE. Administration of corticosteroids resulted in immediate and profound decreases in cytokines, autoantibodies, and inflammatory cells. This case highlights the potential for late-onset changes in humoral and cellular immunity in patients receiving ICI. It also demonstrates the biologic effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management. BMJ Publishing Group 2021-12-07 /pmc/articles/PMC8655605/ /pubmed/34880115 http://dx.doi.org/10.1136/jitc-2021-003585 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L Karp, David Li, Quan-Zhen Wakeland, Edward K Gerber, David E Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title | Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title_full | Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title_fullStr | Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title_full_unstemmed | Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title_short | Humoral and cellular correlates of a novel immune-related adverse event and its treatment |
title_sort | humoral and cellular correlates of a novel immune-related adverse event and its treatment |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655605/ https://www.ncbi.nlm.nih.gov/pubmed/34880115 http://dx.doi.org/10.1136/jitc-2021-003585 |
work_keys_str_mv | AT gonuguntaamrits humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT vonitzsteinmitchells humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT mumosleyhong humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT fattahfarjana humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT farrarjdavid humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT mobelyangela humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT rashdansawsan humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT laisunny humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT bhaisalmanf humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT bermasbonniel humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT karpdavid humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT liquanzhen humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT wakelandedwardk humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment AT gerberdavide humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment |